新股消息 | 轩竹生物再度递表港交所 有超过十种药物资产在积极开发中

Core Viewpoint - XuanZhu Biotech Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CICC as the sole sponsor, following a previous submission on November 25, 2024 [1][4]. Company Overview - XuanZhu Biotech is a Chinese biopharmaceutical company with over ten drug assets actively under development, focusing on unmet medical needs in gastrointestinal diseases, oncology, and non-alcoholic steatohepatitis (NASH) [4][5]. - The company has three core products: KBP-3571 (NDA approved for gastrointestinal diseases), XZP-3287 (NDA approved for targeted breast cancer), and XZP-3621 (NDA submitted for targeted non-small cell lung cancer) [4][5][7]. Product Pipeline - The company is developing a robust pipeline with a phased development strategy for each key indication, including expanding the indication for KBP-3571 to gastroesophageal reflux disease [5][7]. - In oncology, XuanZhu Biotech has two core products, XZP-3287 and XZP-3621, with additional assets in various stages of clinical trials [7]. Financial Performance - For the fiscal years ending December 31, 2023, and 2024, the company reported revenues of RMB 29,000 and RMB 30,094,000, respectively, with significant losses reported [8]. - The total comprehensive losses for the same periods were approximately RMB 300.56 million and RMB 556.43 million, indicating a trend of increasing financial challenges [8].